Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Thomas A. Marciniak"'
Publikováno v:
TH Open, Vol 01, Iss 02, Pp e101-e105 (2017)
Abstract Background The U.S. Food and Drug Administration (FDA) Adverse Event (AE) Reporting System (FAERS) is a global passive surveillance repository requiring mandatory updates by pharmaceutical manufacturers. Oral antiplatelet agents (OAAs) inc
Externí odkaz:
https://doaj.org/article/ca4f33bbf1d245a181b51523dcd89fbe
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year
Autor:
Victor L. Serebruany, Jean-Francois Tanguay, Milana L. Gurvich, Thomas A. Marciniak, Dan Atar
Publikováno v:
The American Journal of Medicine. 136:484-488
Autor:
Victor L. Serebruany, Jean-Francois Tanguay, Milana L. Gurvich, Thomas A. Marciniak, Dan Atar
Publikováno v:
American Journal of Therapeutics.
Autor:
James Swan, Cheol-Whan Lee, Kiyuk Jang, Wolfgang Eisert, Mario Alberto Benavides, Victor L. Serebruany, Junghan Yoon, Jean-François Tanguay, Moo Hyun Kim, Thomas A. Marciniak, Hector A. Cabrera-Fuentes
Publikováno v:
American Journal of Therapeutics
Background Excess vascular deaths in the PLATO trial comparing ticagrelor to clopidogrel have been repeatedly challenged by the Food and Drug Administration (FDA) reviewers and academia. Based on the Freedom of Information Act, BuzzFeed won a court o
Publikováno v:
The American Journal of Medicine. 133:347-351
Background Ivabradine, a heart rate-slowing drug used to treat heart failure and (in Europe) angina, had varying impacts upon cardiovascular events in its 3 large outcome trials. Food and Drug Administration (FDA) analyses may explain the reasons for
Publikováno v:
American Journal of Therapeutics. 26:e417-e420
BACKGROUND Tegaserod, a serotonin (5-HT4) agonist initially approved for constipation but withdrawn from use in 2007 because of concerns about cardiovascular adverse effects, was resubmitted to the Food and Drug Administration (FDA) in 2018 for use i
Publikováno v:
International journal of clinical practiceREFERENCES. 75(7)
PURPOSE The FDA-issued PLATO trial dataset revealed that some primary death causes (PDCs) were inaccurately reported favouring ticagrelor. However, the PLATO Investigators operated the shorter death list of uncertain quality. We compared if PDC match
Autor:
Thomas A. Marciniak, M.D.
Provides the details of a correction and updates to the 2010 Nissen meta-analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee80359471da152e33ba35d005472b5d
Publikováno v:
The BMJ
Objectives To conduct a systematic review and meta-analysis of the effects of rosiglitazone treatment on cardiovascular risk and mortality using multiple data sources and varying analytical approaches with three aims in mind: to clarify uncertainties
Publikováno v:
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open, Vol 02, Iss 01, Pp e28-e32 (2018)
TH Open, Vol 02, Iss 01, Pp e28-e32 (2018)
Whether aggressive prolonged dual antiplatelet therapy (DAPT) promotes solid cancer risks remains a critical unsolved issue. Since the evidence from randomized trials, affiliated U.S. Food and Drug Administration (FDA) reviews, meta-analyses, and nat